登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《NEJM，7月14日，An mRNA Vaccine against SARS-CoV-2 — Preliminary Report》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-07-28

  • An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

    List of authors.

    Lisa A. Jackson, M.D., M.P.H., Evan J. Anderson, M.D., Nadine G. Rouphael, M.D., Paul C. Roberts, Ph.D., Mamodikoe Makhene, M.D., M.P.H., Rhea N. Coler, Ph.D., Michele P. McCullough, M.P.H., James D. Chappell, M.D., Ph.D., Mark R. Denison, M.D., Laura J. Stevens, M.S., Andrea J. Pruijssers, Ph.D., Adrian McDermott, Ph.D., et al., for the mRNA-1273 Study Group*

    Abstract

    BACKGROUND

    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein.

    METHODS

    We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 μg, 100 μg, or 250 μg. There were 15 participants in each dose group.

  • 原文来源：https://www.nejm.org/doi/full/10.1056/NEJMoa2022483?query=featured_home
130浏览量
原文链接
相关报告

  • 《Immunity，3月7日，SARS-CoV-2 vaccines: status report》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-30
    • SARS-CoV-2 vaccines: status report Fatima Amanat 1,2 and Florian Krammer2 1Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA 2Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 170,000 individuals and caused more than 6500 deaths globally. Here we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to have an impact on the first wave of a potential pandemic. Nevertheless, important lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.
    99浏览量
    原文链接

  • 《Prnewswire，2月14日，Recbio Provides Updates on First Lyophilized mRNA Vaccine and Pre-clinical Data Showing Long-term stability and Strong immunogenicity against SARS-CoV-2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：YUTING
    • 发布时间：2022-02-23
    • TAIZHOU, China, Feb. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (Recbio), a China-based company focused on the development of innovative vaccines for major diseases, announced preclinical data of its subsidiary Wuhan Recogen Biotechnology Co., Ltd. (Recogen) on lyophilized mRNA vaccine. The lyophilized mRNA-LNP nanoparticle vaccine is delivered by an LNP delivery system and achieved stability at 4℃ and 25℃ based on a self-developed lyophilization technology. The vaccine can be stored and transported in conventional cold chain conditions, greatly improving the accessibility of mRNA vaccine. The results have been on the preprint server bioRxiv According to this paper, Recogen developed the lyophilized mRNA-LNP nanoparticle vaccine targeting wild-type, Delta and Omicron SARS-CoV-2 variant, and the data showed that the lyophilized process did not affect the key physicochemical parameters, biological activity and immunogenicity of the vaccine. Notably, the Delta-specific mRNA vaccine can induce a high-level neutralization response in mice against both the wild-type and the current global pandemic strain Omicron. A virus challenge study of hACE2 transgenic mice shows the lyophilized mRNA-Delta vaccine is highly immunogenic and can fully protect the challenged mice from SARS-COV-2 infection and clear the virus. Vaccines have become the world's most cost-effective tool to respond to the COVID-19. As of now, more than 10 billion doses of COVID-19 vaccine have been administered globally. However, only 10% of people in low-income countries have received at least one dose of vaccine. Therefore, it is particularly important to develop an mRNA vaccine that can be transported in conventional cold-chain and be stored at 2℃~8℃, or at room temperature stably for broad application. Recogen successfully achieved the lyophilization of mRNA-LNP vaccine. This lyophilization platform could significantly improve the accessibility of mRNA vaccines or therapeutics, particularly in remote regions. The paper links: https://www.biorxiv.org/content/10.1101/2022.02.10.479867v2.full.pdf
    116浏览量
    原文链接